Freedom Investment Management Inc. Sells 3,223 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Freedom Investment Management Inc. trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 16.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 15,910 shares of the biopharmaceutical company’s stock after selling 3,223 shares during the quarter. Freedom Investment Management Inc.’s holdings in Catalyst Pharmaceuticals were worth $316,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of CPRX. Vanguard Group Inc. lifted its position in shares of Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after acquiring an additional 860,244 shares during the period. Dimensional Fund Advisors LP grew its holdings in Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after purchasing an additional 263,099 shares during the period. Pacer Advisors Inc. increased its stake in Catalyst Pharmaceuticals by 130,918.8% in the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after purchasing an additional 2,965,310 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Catalyst Pharmaceuticals by 15.2% during the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after purchasing an additional 287,300 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Catalyst Pharmaceuticals by 1.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock worth $19,439,000 after purchasing an additional 22,860 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Citigroup boosted their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Truist Financial lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Stephens began coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and an average price target of $31.14.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 1.2 %

Shares of CPRX stock opened at $22.07 on Friday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.00 and a 12-month high of $24.27. The company has a 50 day moving average of $21.26 and a 200-day moving average of $18.76. The firm has a market cap of $2.63 billion, a P/E ratio of 18.70, a PEG ratio of 3.44 and a beta of 0.75.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.